Market News

Teladoc Health Reports Mixed Results In 1Q; Shares Drop 5.5%

Teladoc Health’s (TDOC) shares fell 5.5% in extended trading on Wednesday as losses for the provider of  virtual healthcare solutions widened in the first quarter. The company reported a net loss of $199.6 million compared to a loss of $29.6 million in the same quarter of last year.

A diluted net loss of $1.31 per share was wider than analysts’ expectations for a loss of $0.54 per share. However, revenues jumped 151% year-on-year to $453.7 million, beating consensus estimates of $451.9 million.

Teladoc Health’s CEO, Jason Gorevic said, “After a transformational year, Teladoc Health continues to show strong momentum by delivering record results across the business. Consumers are embracing our whole-person virtual care offerings, engaging with multiple products and coming to us for more of their health needs.”

“As our integration accelerates, we are leading the way in whole-person care, unlocking the full spectrum of healthcare in one unified and personalized consumer experience,” Gorevic added.

Access fees of $388.2 million rose 183% year-on-year and comprised around 85.5% of the company’s total revenues of $453.7 million. The company’s paid memberships in the United States hit 51.5 million in 1Q, a rise of 20% year-on-year.

For the second quarter, TDOC expects revenues to be between $495 million and $505 million and adjusted EBITDA to land between $61 million and $64 million. For FY21, the company raised its revenue outlook and has forecast revenues of $1,970 million to $2,020 million and adjusted EBITDA of between $255 million and $275 million. (See Teladoc Health stock analysis on TipRanks)

Following the earnings, Oppenheimer analyst Michael Wiederhorn lowered the price target from $270 to $250 but reiterated a Buy on the stock. Wiederhorn said in a note to investors, “The results reflect the first full quarter with Livongo, along with 69% organic growth…”

“Due to improved outlook, we raise our 2021/2022 adj. EBITDA estimates to $273M/$424M from $267M/$418M, but due to the quarter/below-the-line items, we lower our GAAP 2021/2022E EPS estimates to ($2.42)/($0.82) from ($0.29)/$0.45…” Wiederhorn added.

Shares have crashed approximately 32% in the past three months.

Overall, consensus on the Street is that TDOC is a Moderate Buy based on 13 Buys and 6 Holds. The average analyst price target of $255.61 implies upside potential of about 37.2% from current levels.

Related News:
Amgen’s 1Q Results Disappoint; Shares Drop 8%
UPS Delivers A Blowout Quarter In 1Q
Alphabet Pops 4% After A Blowout Quarter, Google Cloud & Ad Revenues Outperform

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More